EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T. McCabe, Caretha L. Creasy, Heidi M. Ott et al.|Nature|2012Cited by 1.8k
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLCHelai P. Mohammad, Ryan G. Kruger, Chandrashekhar D. Kamat et al.|Cancer Cell|2015Cited by 518
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancerPaweł K. Mazur, Or Gozani, Nicolas Reynoird et al.|Nature|2014Cited by 412
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2Sharad K. Verma, William H. Miller, Xinrong Tian et al.|ACS Medicinal Chemistry Letters|2012Cited by 377
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of RapamycinSteven D. Knight, Dashyant Dhanak, Nicholas D. Adams et al.|ACS Medicinal Chemistry Letters|2010Cited by 374